These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

706 related articles for article (PubMed ID: 33712044)

  • 1. Sustained remission after haploidentical bone marrow transplantation in a child with refractory systemic juvenile idiopathic arthritis.
    Morelle G; Castelle M; Pinto G; Breton S; Bendavid M; Boussard C; Mouy R; Bader-Meunier B; Semeraro M; Faye A; Cavazzana M; Neven B; Blanche S; Quartier P; Moshous D
    Pediatr Rheumatol Online J; 2021 Mar; 19(1):27. PubMed ID: 33712044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case report: Emapalumab for active disease control prior to hematopoietic stem cell transplantation in refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome.
    Chellapandian D; Milojevic D
    Front Pediatr; 2023; 11():1123104. PubMed ID: 36891226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report: Success of allogeneic hematopoietic stem cell transplantation for refractory systemic-onset juvenile idiopathic arthritis.
    Beaufils C; Proulx C; Blincoe A; Teira P; Bittencourt H; Cellot S; Duval M; Morin MP; De Bruycker JJ; Couture J; Samaan K; Decaluwe H; Kleiber N; El-Jalbout R; Touzot F; Haddad E; Barsalou J
    Front Med (Lausanne); 2023; 10():1275927. PubMed ID: 37908851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graft-versus-Host Disease Prophylaxis with Post-Transplantation Bendamustine in Patients with Refractory Acute Leukemia: A Dose-Ranging Study.
    Moiseev I; Bondarenko S; Morozova E; Vlasova Y; Dotsenko A; Epifanovskaya O; Babenko E; Botina A; Baykov V; Surkova E; Lapin S; Beynarovich A; Borzenkova E; Golosgchapov O; Kanunnikov M; Kudyasheva O; Ovechkina V; Pirogova O; Porunova V; Rudakova T; Smikova O; Smirnova A; Afansyev B
    Transplant Cell Ther; 2021 Jul; 27(7):601.e1-601.e7. PubMed ID: 33845259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis.
    M F Silva J; Ladomenou F; Carpenter B; Chandra S; Sedlacek P; Formankova R; Grandage V; Friswell M; Cant AJ; Nademi Z; Slatter MA; Gennery AR; Hambleton S; Flood TJ; Lucchini G; Chiesa R; Rao K; Amrolia PJ; Brogan P; Wedderburn LR; Glanville JM; Hough R; Marsh R; Abinun M; Veys P
    Blood Adv; 2018 Apr; 2(7):777-786. PubMed ID: 29618462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies.
    Yang T; Lin Q; Ren J; Chen P; Yuan X; Luo X; Liu T; Zheng J; Zheng Z; Zheng X; Chen X; Zhang L; Zheng H; Chen Z; Hua X; Le S; Li J; Chen Z; Hu J
    Oncotarget; 2016 Nov; 7(48):78773-78786. PubMed ID: 27705929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease.
    Wiebking V; Hütker S; Schmid I; Immler S; Feuchtinger T; Albert MH
    Ann Hematol; 2017 Aug; 96(8):1373-1377. PubMed ID: 28573314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.
    Zhang C; Kong PY; Li S; Chen T; Ni X; Li Y; Wang M; Liu Y; Gao L; Gao L; Peng XG; Sun AH; Wang P; Yang Z; Zhang X; Qian C
    J Immunother; 2018; 41(6):306-311. PubMed ID: 29864079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of allogeneic bone marrow transplantation from an HLA-identical sibling or a matched unrelated donor in the treatment of children with juvenile chronic myeloid leukaemia.
    Locatelli F; Pession A; Comoli P; Bonetti F; Giorgiani G; Zecca M; Taibi RM; Mongini ME; Ambroselli F; de Stefano P; Severi F; Paolucci G
    Br J Haematol; 1996 Jan; 92(1):49-54. PubMed ID: 8562410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
    Carella AM; Lerma E; Dejana A; Corsetti MT; Celesti L; Bruni R; Benvenuto F; Figari O; Parodi C; Carlier P; Florio G; Lercari G; Valbonesi M; Casarino L; De Stefano F; Geniram A; Venturino M; Tedeschi L; Palmieri G; Piaggio G; Podestà M; Frassoni F; Van Lint MT; Marmont AM; Bacigalupo A
    Haematologica; 1998 Oct; 83(10):904-9. PubMed ID: 9830799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation.
    Duléry R; Bastos J; Paviglianiti A; Malard F; Brissot E; Battipaglia G; Médiavilla C; Giannotti F; Banet A; de Wyngaert ZV; Ledraa T; Belhocine R; Sestili S; Adaeva R; Lapusan S; Isnard F; Legrand O; Vekhoff A; Rubio MT; Ruggeri A; Mohty M
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1407-1415. PubMed ID: 30871978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical study of allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute lymphocytic leukemia].
    Ma X; Wu DP; Sun AN; Fu ZZ; Tang XW; Wu XJ; Liu YJ; Qiu HY; Miao M; Han Y; Jin ZM; Zhao Y; Xue SL; Wang Y; Chen SN; He GS; Zhou HX; Chang HR
    Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):73-6. PubMed ID: 19563014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide Plus Thiotepa Improves Donor Engraftment in Patients with Sickle Cell Anemia: Results of an International Learning Collaborative.
    de la Fuente J; Dhedin N; Koyama T; Bernaudin F; Kuentz M; Karnik L; Socié G; Culos KA; Brodsky RA; DeBaun MR; Kassim AA
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1197-1209. PubMed ID: 30500440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor.
    Blaise D; Fürst S; Crocchiolo R; El-Cheikh J; Granata A; Harbi S; Bouabdallah R; Devillier R; Bramanti S; Lemarie C; Picard C; Chabannon C; Weiller PJ; Faucher C; Mohty B; Vey N; Castagna L
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):119-24. PubMed ID: 26341397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of CD34 Cell Dose and Conditioning Regimen on Outcomes after Haploidentical Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Relapsed/Refractory Severe Aplastic Anemia.
    Arcuri LJ; Nabhan SK; Cunha R; Nichele S; Ribeiro AAF; Fernandes JF; Daudt LE; Rodrigues ALM; Arrais-Rodrigues C; Seber A; Atta EH; de Oliveira JSR; Funke VAM; Loth G; Junior LGD; Paz A; Calixto RF; Gomes AA; Araujo CES; Colturato V; Simoes BP; Hamerschlak N; Flowers ME; Pasquini R; Rocha V; Bonfim C
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2311-2317. PubMed ID: 32949751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Haploidentical allogenetic hematopoietic stem cell transplantation for X-linked adrenoleukodystrophy].
    Chen Y; Zhang XH; Xu LP; Liu KY; Qin J; Yang YL; Huang XJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Jun; 51(3):409-413. PubMed ID: 31209410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.